Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics and Agensys, a subsidiary of Tokyo-based Astellas Pharma, are set to jointly develop a second antibody-drug conjugate (ADC) ASG-5ME, under their existing collaboration agreement which was originally signed in January 2007.
Subscribe to our email newsletter
ASG-22ME is an ADC composed of a fully human antibody directed to Nectin-4, an antigen expressed in multiple cancers including bladder, breast, lung and pancreatic cancers.
ASG-5ME currently is in Phase I clinical trials to investigate the safety, tolerability, pharmacokinetic profile and antitumor activity of escalating doses of ASG-22ME for the patients who are suffering from pancreatic and prostate cancer.
Earlier, Agensys has filed an investigational new drug (IND) application for a Phase I trial of ASG-22ME during first quarter of 2011 with the US Food and Drug Administration (FDA).
Seattle Genetics chief business officer Eric Dobmeier said ASG-22ME is the second ADC they are co-developing under their collaboration with Agensys/Astellas, and the 15th ADC using Seattle Genetics’ technology in clinical development across both their internal pipeline and collaborator programs.
Agensys president and CEO Sef Kurstjens said these two co-development programs with Seattle Genetics, coupled with other internal programs such as their AGS-16M8F ADC that is in a phase I trial for renal cell carcinoma, demonstrate their commitment to ADCs and the strength of their growing oncology pipeline.